Press Releases Year None2021202020192018201720162015201420132012 Mar 23 Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients Mar 17 Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2021 for Remarkable Research on Infinite Matching Algorithms, Machine Learning to Evaluate New Medicines and Water Filtration Mar 15 Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival Mar 4 FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma Feb 27 Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma Feb 26 EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients Feb 25 Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial Feb 22 FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50% Feb 12 Regeneron Announces Investor Conference Presentations Feb 12 The Lancet Publishes Libtayo® (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50% First page « Previous page ‹ Page 1 Current page 2 Page 3 Next page › Last page »